FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.
What happened
FDA inspected GC America's drug manufacturing facility in Alsip, Illinois, from November 3 to 7, 2025. The agency found failures to test components for identity and full specifications, an inadequate stability program, and quality-unit problems including uncontrolled analytical data and missing annual product reviews. FDA reviewed the company's November 21, 2025 response and said it was inadequate.
What FDA found
FDA cited the company for failing to test each component lot for identity and for conformity with written specifications for purity, strength, and quality before use, including high-risk components.
21 CFR 211.84(d)(1) and 211.84(d)(2)FDA cited the company for lacking a written stability program with adequate long-term or accelerated data to support storage conditions and labeled expiration dates.
21 CFR 211.166(a) and 211.166(b)FDA cited the quality unit for not adequately overseeing manufacturing, including an uncontrolled password on a meter-linked laptop and automatic deletion of analytical data with no audit trail or records procedure.
21 CFR 211.22(d); 21 CFR 211.68(b)FDA cited the company for not performing annual product reviews since 2018 and for lacking a written procedure for them.
21 CFR 211.180(e)
What FDA wants
FDA tells GC America to correct the violations promptly and respond in writing within 15 working days with detailed corrective actions, risk assessments, procedures, and test results for high-risk components; FDA also recommends retaining a qualified CGMP consultant.
Who should pay attention
- drug companies that buy or distribute GC America products
- OTC drug brands using components or finished products from this site
- quality teams managing supplier qualification and component identity testing
This is a summary. Read the original letter on fda.gov.